CytoVale is a biotechnology research company that uses early detection strategies for auto-immune diseases. The company has a mission of using diagnostic interventions to create faster, easier-to-implement medical treatment for patients. Other features of CytoVale are microfluidics and biophysical machine learning. CytoVale was founded by Ajay Shah and Dino Di Carlo in 2013 and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for CytoVale, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access CytoVale’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like CytoVale.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

CytoVale investors also invested in these private companies

Norwest Venture Partners
Dolby Family Ventures
U.S. Department of Health and Human Services
Global Health Investment Fund
Kayyak Ventures
Pathway Bioventures
Biomedical Advanced Research and Development Authority
Blackhorn Ventures
Pactolus Ventures
Farmore Capital Group
Breakout Labs
NetScientific

Team

Management Team

Ajay Shah Ph.D
Co-Founder & Chief Executive Officer
Bill Blackledge
Chief Financial Officer
Henry Tse Ph.D
Co-Founder & Chief Technology Officer
Robert Scoggins Ph.D
Chief Medical Officer
Dino Di Carlo Ph.D
Co-Founder & Scientific Advisor

Board Members

David Dolby
Dolby Family Ventures
Jack Fuchs
Blackhorn Ventures
Jordanna Schutz
Pactolus Ventures
Lindy Fishburne
Breakout Labs
Pascal Levensohn
Dolby Family Ventures

Frequently Asked Questions About CytoVale’s Stock

plusminus
Can you buy CytoVale’s stock?
CytoVale is not publicly traded on NYSE or NASDAQ in the U.S. To buy CytoVale’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell CytoVale’s stock?
Yes, you can sell stock of a private company like CytoVale. Forge can help you sell your CytoVale stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is CytoVale’s stock price?
CytoVale is a privately held company and therefore does not have a public stock price. However, you may access CytoVale’s private market stock price with Forge Data.
plusminus
What is CytoVale’s stock ticker symbol?
CytoVale does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Cytovale collects $84M to roll out its rapid ER sepsis diagnostic test
After recently launching its emergency room-focused diagnostic for catching early cases of sepsis, Cytovale has raised $84 million in venture capital funding to bolster the system’s rollout. According to the San Francisco-based company, sepsis contributes to more than one-third of all in-hospital deaths—more than 350,000 annually in the U.S.—with about 80% of patients with the bloodstream condition spending at least some time in the ER.
Cytovale’s test gets FDA 510(k) clearance for early sepsis detection
Medical diagnostics company Cytovale has secured 510(k) clearance from the US Food and Drug Administration (FDA) for IntelliSep, its test for the early detection of sepsis. IntelliSep has been designed to help clinicians recognise sepsis and make time-sensitive critical decisions. It provides test results within ten minutes. It is claimed to be the first FDA-approved diagnostic tool for evaluating cellular host response to help identify patients with sepsis in emergency departments.
Updated on: Feb 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.